Edwards Lifesciences (EW) Price & Analysis

Compare

0 Followers

EW Stock Chart & Stats

CHF68.77

CHF0.00(0.00%)

Market closed

CHF68.77

CHF0.00(0.00%)

Day’s Range― - ―

52-Week RangeCHF66.67 - CHF68.77

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

$39.24B

Enterprise ValueCHF42.41B

Total Cash (Recent Filing)$3.84B

Total Debt (Recent Filing)$700.30M

Price to Earnings (P/E)34.3

BetaN/A

Next Earnings

Feb 04, 2026

EPS Estimate

0.5

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.54

Shares Outstanding587,100,000

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)4.43

Price to Sales (P/S)8.13

P/FCF Ratio152.63

Enterprise Value/Market Cap1.08

Enterprise Value/Revenue7.21

Enterprise Value/Gross Profit9.21

Enterprise Value/Ebitda24.90

Forecast

1Y Price Target

$74.73

Price Target Upside8.67% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering24

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Data And ApprovalsThe presentation of successful mitral replacement data, expected to lead to FDA approval, completes the company's 'toolbox' for mitral market opportunities.

Earnings And Financial PerformanceThe company's Q3 revenue and EPS soundly beat Street forecasts, showcasing strong financial performance.

Product Growth And Market ExpansionTAVR growth is improving, bolstered by the potential of asymptomatic adoption, and EW’s TMTT business is better positioned.

Bears Say

Clinical Trial PerformanceThe performance of TAVR in the P3 trial continues to get worse, and the long-term outcomes should still be monitored and questioned.

Growth Sustainability ConcernsThere is a lack of conviction in the sustainability of upside drivers to the previous mid-to-high single digit growth target, thus reiterating a Neutral rating.

Regulatory UncertaintyTiming for CMS coverage is still uncertain, especially with government shutdown.

Edwards Lifesciences News

Edwards Lifesciences price target raised to $90 from $87 at Truist

Truist raised the firm’s price target on Edwards Lifesciences (EW) to $90 from $87 and keeps a Hold...

5d ago

Edwards Lifesciences price target raised to $104 from $94 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Edwards Lifesciences (EW) to $104 from $94 and keeps a...

5d ago

Edwards Lifesciences price target raised to $90 from $85 at UBS

UBS raised the firm’s price target on Edwards Lifesciences (EW) to $90 from $85 and keeps a Neutral...

5d ago

Edwards Lifesciences price target raised to $84 from $81 at Canaccord

Canaccord raised the firm’s price target on Edwards Lifesciences (EW) to $84 from $81 and keeps a Hold...

5d ago

Edwards Lifesciences upgraded to Outperform at Raymond James

Raymond James analyst Jayson Bedford upgraded Edwards Lifesciences (EW) to Outperform from Market Perform with a $96 price...

5d ago

Edwards Lifesciences price target raised to $92 from $88 at Evercore ISI

Evercore ISI raised the firm’s price target on Edwards Lifesciences (EW) to $92 from $88 and keeps an...

8d ago

Edwards Lifesciences price target raised to $104 from $94 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Edwards Lifesciences (EW) to $104 from $94 and keeps a...

8d ago

Edwards Lifesciences price target raised to $95 from $89 at RBC Capital

RBC Capital raised the firm’s price target on Edwards Lifesciences (EW) to $95 from $89 and keeps an...

8d ago

Edwards Lifesciences price target raised to $90 from $85 at JPMorgan

JPMorgan raised the firm’s price target on Edwards Lifesciences (EW) to $90 from $85 and keeps a Neutral...

8d ago

Edwards Lifesciences price target raised to $83 from $81 at Baird

Baird analyst David Rescott raised the firm’s price target on Edwards Lifesciences (EW) to $83 from $81 and...

8d ago

Edwards Lifesciences Reports Strong Earnings and Growth

Edwards Lifesciences Corp. (($EW)) has held its Q3 earnings call. Read on for the main highlights of the...

8d ago

Edwards Lifesciences Reports Strong Q3 2025 Growth

Edwards Lifesciences Corp. ( ($EW) ) has released its Q3 earnings. Here is a breakdown of the information...

8d ago

Edwards Lifesciences Announces CFO Transition Plan

Edwards Lifesciences ( ($EW) ) just unveiled an announcement. On October 30, 2025, Edwards Lifesciences announced that its...

9d ago

Edwards Lifesciences: Hold Rating Amidst Stable TAVR vs. SAVR Trial Outcomes

In a report released today, Josh Jennings from TD Cowen maintained a Hold rating on Edwards Lifesciences, with...

11d ago

EW FAQ

What was Edwards Lifesciences’s price range in the past 12 months?

Edwards Lifesciences lowest stock price was CHF66.67 and its highest was CHF68.77 in the past 12 months.

What is Edwards Lifesciences’s market cap?

Edwards Lifesciences’s market cap is $39.24B.

When is Edwards Lifesciences’s upcoming earnings report date?

Edwards Lifesciences’s upcoming earnings report date is Feb 04, 2026 which is in 88 days.

How were Edwards Lifesciences’s earnings last quarter?

Edwards Lifesciences released its earnings results on Oct 30, 2025. The company reported CHF0.541 earnings per share for the quarter, beating the consensus estimate of CHF0.481 by CHF0.06.

Is Edwards Lifesciences overvalued?

According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Edwards Lifesciences pay dividends?

Edwards Lifesciences does not currently pay dividends.

What is Edwards Lifesciences’s EPS estimate?

Edwards Lifesciences’s EPS estimate is 0.5.

How many shares outstanding does Edwards Lifesciences have?

Edwards Lifesciences has 587,100,000 shares outstanding.

What happened to Edwards Lifesciences’s price movement after its last earnings report?

Edwards Lifesciences reported an EPS of CHF0.541 in its last earnings report, beating expectations of CHF0.481. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Edwards Lifesciences?

Currently, no hedge funds are holding shares in CH:EW

Edwards Lifesciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

13.59%

Trailing 12-Months

Asset Growth

2.32%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences (EW) Earnings & Revenues

Historic Earnings Reports

EW Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Edwards Lifesciences reported strong quarterly performance with significant sales growth across multiple segments, increased full-year guidance, and positive clinical data presentations. However, there were some concerns about declining gross profit margins and upcoming changes in financial leadership.View all CH:EW earnings summaries

EW Net sales Breakdown

75.49% Transcatheter Aortic Valve Replacement

18.04% Surgical Structural Heart

6.47% Transcatheter Mitral and Tricuspid Therapies

EW Stock 12 Month Forecast

Average Price Target

CHF74.73

▲(8.67% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"65":"CHF65","84":"CHF84","69.75":"CHF69.8","74.5":"CHF74.5","79.25":"CHF79.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":83.70699688,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF83.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":74.7326409645,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF74.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":66.80462251,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF66.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[65,69.75,74.5,79.25,84],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,68.772,69.92084591384616,71.06969182769231,72.21853774153847,73.36738365538461,74.51622956923077,75.66507548307693,76.81392139692308,77.96276731076924,79.11161322461538,80.26045913846154,81.4093050523077,82.55815096615385,{"y":83.70699688,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,68.772,69.23051084342308,69.68902168684616,70.14753253026923,70.60604337369232,71.06455421711539,71.52306506053847,71.98157590396154,72.44008674738463,72.8985975908077,73.35710843423078,73.81561927765385,74.27413012107692,{"y":74.7326409645,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,68.772,68.62066327000001,68.46932654000001,68.31798981,68.16665308,68.01531635,67.86397962000001,67.71264289,67.56130616,67.40996943,67.2586327,67.10729597,66.95595924,{"y":66.80462251,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":68.772,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >